---
title: "RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286342985.md"
description: "RBC Capital has reaffirmed a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $51.00, while the shares closed at $11.43. Analyst Brian Abrahams, a 5-star analyst, has an average return of 10.1% and a 51.10% success rate. The consensus on Corbus is a Strong Buy with an average price target of $40.78, indicating a potential upside of 256.78%. Oppenheimer also reiterated a Buy rating with a $54.00 price target."
datetime: "2026-05-14T01:48:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286342985.md)
  - [en](https://longbridge.com/en/news/286342985.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286342985.md)
---

# RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

In a report released on May 12, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals, with a price target of $51.00. The company’s shares closed yesterday at $11.43.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Abrahams is a 5-star analyst with an average return of 10.1% and a 51.10% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, BioCryst, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $40.78, which is a 256.78% upside from current levels. In a report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $54.00 price target.

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)
- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)

## Related News & Research

- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)